Eosinophilic leukaemia

British Medical Bulletin

Volumn 81-82, Issue 1, 2007, Pages 115-127

  Fletcher, Sarah ^a   Bain, Barbara ^a,b  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b ST MARY S HOSPITAL   (United Kingdom)

Author keywords

Eosinophilia; Eosinophilic; Leukaemia

Indexed keywords

HYDROXYUREA; IMATINIB; PLATELET DERIVED GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PROTEIN TYROSINE KINASE INHIBITOR; STEROID;

ATYPICAL CHRONIC MYELOID LEUKEMIA; CANCER CLASSIFICATION; CHRONIC MYELOID LEUKEMIA; CHRONIC MYELOMONOCYTIC LEUKEMIA; CLINICAL FEATURE; DIFFERENTIAL DIAGNOSIS; EOSINOPHIL; EOSINOPHILIA; EOSINOPHILIC LEUKEMIA; GENE REARRANGEMENT; HEMATOLOGY; HUMAN; HYPEREOSINOPHILIC SYNDROME; IDIOPATHIC DISEASE; JUVENILE MYELOMONOCYTIC LEUKEMIA; MEDICAL RESEARCH; MEDLINE; MOLECULAR GENETICS; PATIENT CARE; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SCIENTIFIC LITERATURE; TREATMENT OUTCOME; ADULT; FEMALE; GENE FUSION; GENETICS; MALE; MIDDLE AGED;

ADULT; DIAGNOSIS, DIFFERENTIAL; FEMALE; GENE FUSION; GENE REARRANGEMENT; HUMANS; HYPEREOSINOPHILIC SYNDROME; MALE; MIDDLE AGED; PROGNOSIS;

EID: 34347372106     PISSN: 00071420     EISSN: 14718391     Source Type: Journal    
DOI: 10.1093/bmb/ldm008     Document Type: Review

References (32)

1. Bain B, Pierre R, Imbert M, Vardiman JW, Brunning RD, Flandrin G (2001) Chronic eosinophilic leukaemia and the hypereosinophilic syndrome. In Jaffe ES, Harris NL, Stein H Vardiman JW (eds) World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: IARC Press, 29-31.
2. Bain BJ (2002) An overview of translocation-related oncogenesis in the chronic myeloid leukaemias. Acta Haematol, 107, 57-63.
3. Ryan ET, Wilson ME, Kain KC (2002) Illness after international travel. N Engl J Med, 347, 505-516.
4. Bain BJ (2006) Blood Cells, 4th ed. Oxford: Blackwell Publishing.
5. Simon HU, Plötz SG, Dummer R, Blaser K (1999) Abnormal clones of interleukin-5-producing T cells in idiopathic eosinophilia. N Engl J Med, 341, 1112-1120.
6. Gotlib J, Cross NCP, Gilliland DG (2006) Eosinophilic disorders: molecular pathogenesis, new classification, and modern therapy. Best Pract Res Clin Haematol, 19, 535-569.
7. Cools J, DeAngelo DJ, Gotlib J et al. (2003) A tyrosine kinase created by the fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med, 348, 1201-1214.
8. Spry C (1980) Discussion: management of the idiopathic hypereosinophilic syndrome. In Mahmoud AAF, Austere KP, Simon AS (eds) The Eosinophil in Health and Disease. New York: Grune & Stratton, 341.
9. Robyn J, Lemery S, McCoy JP et al. (2006) Multilineage involvement of the fusion gene in patients with FIP1L1/PDGFRA-positive hypereosinophilic syndrome. Br J Haematol, 132, 286-292.
10. Baxter EJ, Hochhaus A, Bolufer P et al. (2002) The t(4;22)(q12;q11) in atypical chronic myeloid leukaemia fuses BCR to PDGFRA. Hum Mol Genet, 11, 1391-1397.
11. Score J, Curtis C, Waghorn K et al. (2006) Identification of a novel imatinib responsive KIF5B-PDGFRA fusion gene following screening for PDGFRA overexpression in patients with hypereosinophilia. Leukemia, 20, 827-832.
12. Walz C, Curtis C, Schnittger S et al. (2006) Transient response to imatinib in a chronic eosinophilic leukaemia associated with ins(9;4)(q33;q12q25) and a CDK5RAP2-PDGFRA fusion gene. Genes Chrom Cancer, Epub ahead of print July 14, 2006.
13. Steer J, Cross NCP (2002) Myeloproliferative disorders with translocations of chromosome 5q31-35: role of the platelet-derived growth factor receptor beta. Acta Haematol, 107, 112-122.
14. Wilkinson K, Velloso ER, Lopes LF et al. (2003) Cloning of the t(1;5)(q23;q33) in a myeloproliferative disorder associated with eosinophilia: involvement of PDGFRB and response to imatinib. Blood, 102, 4187-4190.
15. Vizmanos JL, Novo FJ, Roman JP et al. (2004) NIN, a gene encoding a CEP110-like centrosomal protein, is fused to PDGFRB in a patient with a t(5;14)(q33;q24) and an imatinib-responsive myeloproliferative disorder. Cancer Res, 64, 2673-2676.
16. Grand FH, Burgstaller S, Kühr T et al. (2004) p53-Binding protein 1 is fused to the platelet-derived growth factor receptor β in a patient with a t(5;15)(q33;q22) and an imatinib-responsive eosinophilic myeloproliferative disorder. Cancer Res, 64, 7216-7219.
17. Morerio C, Acquila M, Rosanda C et al. (2004) HCMOGT-1 is a novel fusion partner to PDGFRB in juvenile myelomonocytic leukemia with t(5;17)(q33;p11.2). Cancer Res, 64, 2649-2651.
18. Curtis C, Apperley JF, Dang R et al. (2005) The platelet derived growth factor receptor beta fuses to two distinct loci at 3p21 in imatinib responsive chronic eosinophilic leukemia. Blood, 106, 909a.
19. Levine RL, Wadleigh M, Sternberg DW et al. (2005) KIAA1509 is a novel PDGFRB fusion partner in imatinib-responsive myeloproliferative disease associated with a t(5;14)(q33;q32). Leukemia, 19, 27-30.
20. Rosati R, La Starza R, Luciano L et al. (2006) TPM3/PDGFRB fusion transcript and its reciprocal in chronic eosinophilic leukemia. Leukaemia, Epub ahead of print 2006.
21. Macdonald D, Reiter A, Cross NCP (2002) The 8p11 myeloproliferative syndrome: a distinct clinical entity caused by constitutive activation of FGFR1. Acta Haematol, 107, 101-107.
22. Guasch G, Popovici C, Mugneret F et al. (2000) Endogenous retroviral sequence is fused to FGFR1 kinase in the 8p12 stem-cell myeloproliferative disorder with t(8;19)(p12;q13.3). Blood, 101, 286-288.
23. Belloni E, Trubia M, Gasparini P et al. (2005) 8p11 myeloproliferative syndrome with a novel t(7;8) translocation leading to fusion of the FGFR1 and TIF1 genes. Genes Chrom Cancer, 42, 320-325.
24. Walz C, Chase A, Schoch C et al. (2005) The t(1;17)(p11;q23) in the 8p11 myeloproliferative syndrome fuses MYO18A to TGFR1. Leukemia, 19, 1005-1009.
25. Murati A, Amoulet C, Lafage-Pochitaloff M et al. (2005) Dual lympho-myeloproliferative disorder in a patient with t(8;22) with BCR-FGFR1 gene fusion. Int J Oncol, 26, 1485-1492.
26. Roy S, Szer J, Campbell LJ, Juneja S (2002) Sequential transformation of t(8;13)-related disease. Acta Haematol, 107, 95-97.
27. Al-Obaidi MJ, Rymes N, White P et al. (2002) A fourth case of 8p11 myeloproliferative disorder transforming to B-lineage acute lymphoblastic leukaemia. A case report. Acta Haematol, 107, 98-101.
28. Jones AV, Kreil S, Zoi K et al. (2005) Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood, 106, 2162-2168.
29. Apperley J, Gardembas M, Melo J et al. (2002) Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta. N Engl J Med, 347, 481-487.
30. David M, Cross NCP, Burgstaller S et al. (2007) Durable responses to imatinib in patients with PDGFRB fusion gene positive and BCR-ABL negative chronic myeloproliferative disorders. Blood, 109, 61-64.
31. Chen J, DeAngelo DJ, Kutok JL et al. (2004) PKC412 inhibits the zinc finger 198-fibroblast growth factor receptor 1 fusion tyrosine kinase and is active in treatment of stem cell myeloproliferative disorder. Proc Natl Acad Sci USA, 101, 14479-14484.
32. Fletcher S, Bain B (2007) Diagnosis and treatment of hypereosinophilic syndromes. Curr Opin Hematol, 14, 37-42.